EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patterns of Clinical Trial Enrollment for Pediatric Patients With Hepatoblastoma and Wilms Tumor: A Report From the Children's Oncology Group

Pablo S Monterroso iD, Sarah Lucht, Jeannette M Sample iD, Angela D Trobaugh-Lotrario, Helen M Parsons iD, Lucie M Turcotte, David Van Riper, Jenny N Poynter, Erin L Marcotte iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Pablo S Monterroso und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Hepatoblastoma, Wilms Tumor, Clinical Trials as Topic, Liver Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Oncology Group, NCI NIH HHS, Children's Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Published childhood cancer studies have observed differences in therapeutic trial enrollment by race, ethnicity, socioeconomic status (SES), and age at diagnosis. Our study investigates patterns of enrollment for pediatric oncology clinical trials.

Methods

We analyzed differences in Children's Oncology Group clinical trial enrollment in a cohort of pediatric patients with hepatoblastoma ( n = 212) and Wilms tumor ( n = 1107). Relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated for trial enrollment by patient characteristics. Odds ratios (ORs) and 95% CIs were estimated to examine associations between characteristics and three outcomes (therapeutic trial [referent], exclusively non‐therapeutic study, no trial or study). Statistical significance tests were two‐sided.

Results

Approximately half of all cases enrolled in therapeutic trials for both tumor types (Wilms: 48%; hepatoblastoma: 51%). For Wilms tumor, patients diagnosed at ages 3–5 years were more likely to enroll compared to those diagnosed at age < 1 year (RR = 1.06; 95% CI = 1.01, 1.13) and had lower odds of joining exclusively a non‐therapeutic study compared to those diagnosed at age < 1 years (OR = 0.63; 95% CI = 0.44, 0.90). There was no association between race, ethnicity, or SES and enrollment. For hepatoblastoma, no variables indicated any statistically significant difference in enrollment.

Conclusions

Few differences in clinical trial enrollment were observed during periods when trials were available for all risk groups, a promising sign of equity in pediatric oncology clinical trial recruitment. Among Wilms tumor cases, differences in enrollment were observed for age at diagnosis, a potential proxy for disease acuity, which may influence decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatoblastomaWilms TumorClinical Trials as TopicLiver NeoplasmsPatient SelectionKidney NeoplasmsHumansChild, PreschoolFemaleMaleInfantChildAdolescentInfant, Newborn

Stichwörter der Autor:innen

childhood cancerclinical trialspediatricrace and ethnicitysocioeconomic status

Autor:innen und Institutionen

  • Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
  • Environmental Epidemiology Group, Institute for Occupational, Social and Environmental Medicine, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, D…
  • Department of Pediatric Hematology/Oncology, Providence Sacred Heart Children's Hospital, Spokane, Washington, USA.
  • Division of Health Policy and Management, University of Minnesota, Minneapolis, Minnesota, USA.
  • Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Pablo S Monterroso, Jeannette M Sample, Helen M Parsons, Erin L Marcotte

Förderung

  • Children's Oncology Group
  • NCI NIH HHS
  • Children's Cancer Research Fund
  • National Cancer Institute
  • Children’s Oncology Group

Zitieren

APA

Monterroso, P. S., Lucht, S., Sample, J. M., Trobaugh-Lotrario, A. D., Parsons, H. M., Turcotte, L. M., Van Riper, D., Poynter, J. N., & Marcotte, E. L. (2025). Patterns of Clinical Trial Enrollment for Pediatric Patients With Hepatoblastoma and Wilms Tumor: A Report From the Children's Oncology Group. Cancer Medicine. https://doi.org/10.1002/cam4.70692

Vancouver

Monterroso PS, Lucht S, Sample JM, Trobaugh-Lotrario AD, Parsons HM, Turcotte LM, et al. Patterns of Clinical Trial Enrollment for Pediatric Patients With Hepatoblastoma and Wilms Tumor: A Report From the Children's Oncology Group. Cancer Medicine. 2025. doi:10.1002/cam4.70692

BibTeX
@article{Monterroso2025,
  author = {Monterroso, Pablo S and Lucht, Sarah and Sample, Jeannette M and Trobaugh-Lotrario, Angela D and Parsons, Helen M and Turcotte, Lucie M and Van Riper, David and Poynter, Jenny N and Marcotte, Erin L},
  title = {Patterns of Clinical Trial Enrollment for Pediatric Patients With Hepatoblastoma and Wilms Tumor: A Report From the Children's Oncology Group},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70692}
}
Kostenlos starten →